Treatment For OP Poisoning Could Save 200,000 Lives A Year

news headlines

email to a friend

printer friendly

Treatment For OP Poisoning Could Save 200,000 Lives A Year

Main Category: Water - Air Quality / Agriculture
Also Included In: Public Health | Biology / Biochemistry
Article Date: 15 Jan 2013

An enzyme treatment which could neutralise the effects of lethal chemicals responsible for the deaths of hundreds of thousands of people across the world has been developed by experts at the University of Sheffield.

Organophosphorus agents (OP) are used as pesticides in developing countries and acute poisoning is common because of insufficient control, poor storage, ready availability, and inadequate education amongst farmers.

It is estimated about 200,000 people die each year across the world from OP poisoning, through occupational exposure, unintentional use and misuse, mostly in developing countries like India, Pakistan, and Sri Lanka and through deliberate terrorist activities.

OPs include compounds like Tabun, which was developed in 1936 by German scientists during World War II, Sarin, Soman, Cyclosarin, VX, and VR.

Using a modified human enzyme, scientist Professor Mike Blackburn from the University of Sheffield's Department of Molecular Biology and Biotechnology collaborated in a consultancy role with Professor Alexander Gabibov of the Shemyakin-Ovchinnikov Institute, Moscow, and Professor Patrick Masson of the Département de Toxicologie, Centre de Recherches du Service de Santé des Armées, to create a "bioscavenger" which was found to protect mice against the nerve agent VR and showed no lasting effects.

In studies performed at the Institute of Bioorganic Chemistry in Pushchino, Russia, a total of eight mice were treated with the new enzyme after being subjected to enough of the VR agent to kill several of the animals - about 63 mg - and all survived.

Professor Blackburn said: "This current publication describes a novel method to generate a bioscavenger for the Russian VR organophosphorus agent with the key property of being long-acting in the bloodstream.

"That has been achieved by a combination of chemical surface modification (polysialylation) and biotechnology of production (through the use of an in vitro CHO-based expression system employing genes encoding butyrylcholinesterase and a proline-rich peptide under special promoter control).

Original article posted on Medical News Today.
Articles not to be reproduced without permission of Medical News Today

Medical News Today publishes the latest health news and health videos for consumers and health professionals. It has a searchable archive of over 100,000 health news articles.

< back to medical news

For any corrections of factual information, or to contact the editors please use our feedback form.

Send your press releases to